HEPATAMINE 8%
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HEPATAMINE 8% (HEPATAMINE 8%).
HEPATAMINE 8% is a branched-chain amino acid (BCAA) solution that provides leucine, isoleucine, and valine to correct amino acid imbalances in hepatic encephalopathy. It reduces plasma aromatic amino acids (AAA) and increases BCAA, restoring the BCAA/AAA ratio, which decreases false neurotransmitter synthesis in the brain.
| Metabolism | Branched-chain amino acids are primarily metabolized in skeletal muscle via transamination and oxidative decarboxylation; not extensively metabolized in the liver. |
| Excretion | Renal: negligible as intact amino acids; nitrogen waste (urea) excreted renally (80-90% of infused nitrogen). Biliary/fecal: <5%. |
| Half-life | Variable; amino acids in HEPATAMINE 8% are cleared rapidly (t1/2 ~10-20 minutes for free amino acids) due to endogenous metabolism. In hepatic failure, half-life may be prolonged (patients with cirrhosis: up to 60 minutes for certain amino acids). Clinical context: supports continuous infusion for stable plasma levels. |
| Protein binding | <5% (amino acids are not significantly protein-bound in plasma) |
| Volume of Distribution | 0.15-0.25 L/kg (reflects distribution primarily to extracellular fluid; clinical meaning: small Vd indicates limited tissue distribution of free amino acids, which are rapidly metabolized or incorporated into proteins.) |
| Bioavailability | Intravenous: 100% (by definition). No other relevant routes for this formulation. |
| Onset of Action | Intravenous: Rapid; metabolic effects (e.g., improved nitrogen balance) observed within 1-2 hours of infusion initiation. Clinical effect (reversal of hepatic encephalopathy) may require 24-48 hours of continuous infusion. |
| Duration of Action | Intravenous: Duration limited to infusion period; metabolic effects persist for 4-6 hours after discontinuation. Clinical improvement (e.g., encephalopathy resolution) may last days, but depends on underlying hepatic function. |
Intravenous infusion: 125 mL/hr initially, titrate to achieve positive nitrogen balance; typical adult dose: 125 mL/hr to 250 mL/hr via central line, not to exceed 2 g protein equivalent per kg per day.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in patients with renal failure or anuria. For GFR <25 mL/min: avoid use due to risk of azotemia. |
| Liver impairment | Not indicated for hepatic encephalopathy; no adjustment for Child-Pugh class; consider alternative therapies in severe hepatic impairment. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | Use with caution; monitor for fluid overload and electrolyte disturbances; no specific dose adjustment but start at lower end of dosing range. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HEPATAMINE 8% (HEPATAMINE 8%).
| Breastfeeding | No data on excretion in human milk; M/P ratio unknown. Caution advised due to potential for adverse effects in nursing infant; consider benefit of therapy. |
| Teratogenic Risk | No adequate human studies; animal studies not reported. Use only if potential benefit justifies potential risk. Fetal risks unknown across all trimesters. |
| Fetal Monitoring | Monitor hepatic function, serum electrolytes, fluid balance, and signs of infection. Fetal monitoring not specifically indicated but general obstetric surveillance recommended. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to any component","Phenylketonuria (due to phenylalanine content)"]
| Precautions | ["Electrolyte imbalances","Fluid overload","Hypersensitivity reactions","Monitor serum ammonia and clinical status","Use with caution in patients with renal impairment"] |
Loading safety data…
| Fertility Effects | No known direct effects on fertility from HEPATAMINE 8% administration; underlying hepatic disease may impair fertility. |